Sysmex Corporation

Toyo Electric Co., Ltd., a leading manufacturer of loudspeakers (now TOA Corporation), when vice president Taro Nakatani sought a new pillar for the business, went to the United States

Taro Nakaya departs for overseas inspection. Taro Nakaya, former vice president of Toa Electric Co., Ltd., a top manufacturer of loudspeakers, sought a new pillar for the business and traveled to the United States.

Toyo Electric Co., Ltd. (now TOA Corporation) decided to expand into the medical electronic equipment industry

Toa Electric Co., Ltd. (now TOA Corporation) decided to expand into the medical electronic device industry. Established a new laboratory, and three engineers began investigations.

Successfully commercialized Japan's first automatic blood cell counter (Automatic Blood Cell Counter CC-1001)

Successfully commercialized the CC-1001, Japan's first automatic blood cell counter.

Founder Taro Nakatani announced the corporate stance of 'selling counting results'

Founder Taro Nakaya announced the corporate stance of 'selling counting results'.

Started providing academic services, issuing 'MCC News' to hospital laboratories nationwide (MCC: Micro Cell Counter)

First issue of 'MCC News'. Launched the 'Automatic Blood Cell Counter CC-1002'. Started publishing 'MCC News' targeting testing laboratories in hospitals nationwide (MCC: Micro Cell Counter).

Start of diagnostic reagent supply. To measure blood cells, equipment and diagnostic reagents are necessary. In order to deliver accurate counting results to customers, the company, originally an electronics manufacturer, also ventured into providing diagnostic reagents (the first developed diagnostic reagent, Diluent "Cellkit" and Hemolytic agent "Saponin-S").

The East Asia Special Electric Company (now TOA Corporation) established the "ME Equipment Division" (ME = Medical Electronic Equipment).

Developed and launched the first diagnostic reagents in Japan: diluent 'Cell Kit' and hemolysin 'Saponin-S'. As an electrical manufacturer, developed and launched these diagnostic reagents.

Members of the ME Equipment Department at Toa Electric Co., Ltd. (now TOA Corporation). Established the 'ME Equipment Department' (ME = Medical Electronic Equipment) at Toa Electric Co., Ltd.

Established as a sales company. The East Asia Special Electric Company (now TOA Corporation) established East Asia Medical Electronics Co., Ltd. (now Sysmex Corporation) as a sales company for medical electronic equipment manufactured by TOA. Taro Nakaya proposed the "Three安心" as the basic management policy (current founding philosophy).

To improve the reliability of counting results, started providing standard substances used for quality control. To confirm correct blood cell measurement in laboratories, launched a standard substance containing specific blood cell counts, "Cell Check™-B".

Basic management policy 'Three Assurances' (current founding philosophy). Established the 'Basic Philosophy of Our Management' summarizing fundamental thoughts and action guidelines for management.

Members at the time of founding of Toa Medical Electronics Co., Ltd. As a sales company for medical electronic devices manufactured by Toa Electric Co., Ltd. (now Sysmex Corporation), established Toa Medical Electronics Co., Ltd.

Launched 'Cell Check-B', a standard material containing specific blood cell counts, to verify proper blood cell measurement in laboratories.

First overseas base established (Hamburg, Germany).

German Representative Office (Hamburg). Acquired the medical electronic device development and manufacturing division of Toa Electric Co., Ltd. (now TOA Corporation), and established a new company as a clinical testing equipment specialist. First overseas base (Germany).

Transition from a sales company to a specialized manufacturer of clinical testing equipment (integrated manufacturing and sales). Established Kakogawa Factory, consolidating sales, development, production, and general affairs departments (Kakogawa City, Hyogo Prefecture).

Kakogawa Factory (Kakogawa City, Hyogo Prefecture). Established a new Kakogawa Factory in Kakogawa City, Hyogo Prefecture, consolidating sales, development, production, and general affairs departments.

Emphasized the pursuit of quality. Taro Nakaya strongly instructed all employees that "Quality is the heart. It is the life of the company."

Entered the urinalysis field. Launched "Simple Automatic Urine Analyzer TU-100".

Taro Nakaya's passionate speech at the founding memorial deeply permeated the company. Taro Nakaya strongly instructed all employees, 'Quality is the heart. It is the life of the company'.

Launched TU-100, a simple automatic urine analyzer, entering the urine testing field.

Launched Japan's first fully automatic blood cell counter (Fully Automatic Blood Cell Counter CC-710).

Launched CC-710, Japan's first fully automatic blood cell counter.

Expansion into the world's largest market and establishment of a base (San Francisco, USA).

U.S. Representative Office (San Francisco). Began expansion into the U.S. market.

Birth of the "Sysmex" brand. Changed product brand from "Toa" to "Sysmex".

Held the first hematology seminar. Since the desire to "provide the latest information on hematology and be useful to society" led to the holding of a full-scale seminar, the theme was expanded beyond hematology, and it has continued as an "Academic Seminar."

Birth of Sysmex brand. Changed product brand from 'Toa' to 'Sysmex'.

First Sysmex Hematology Seminar. Held the first Sysmex Hematology Seminar.

Achieved complete automation of blood cell count testing. Launched the "Fully Automatic Blood Cell Counter CC-720" equipped with the world's first automatic specimen supply function (Sampler).

CC-720 The world's first automatic sample supply function (sampler) equipped in the "Fully Automated Hematology Analyzer CC-720" launched

Toa Medical Electronics (USA) Inc. Established the local subsidiary Toa Medical Electronics (USA) Inc. (currently Sysmex America, Inc.)

Established a local subsidiary in Europe (Hamburg, Germany). TOA MEDICAL ELECTRONICS (DEUTSCHLAND) GMBH (now Sysmex Europe SE).

Toa Medical Electronics (Deutschland) GmbH Established the local European subsidiary Toa Medical Electronics (Deutschland) GmbH (now Sysmex Europe SE) E Series Launched the "Multi-parameter Automated Hematology Analyzer E Series" which established the "Sysmex" brand overseas

CA-100 Launched the "Automatic Blood Coagulation Analyzer CA-100"

Incorporating ideals of robotics engineering, launched the "Fully Automated Blood Coagulation Analyzer CA-3000" which enables random processing for each sample

Strengthened development system in blood coagulation, immunology, and urinalysis. Established Kobe Factory in the Shinkami Industrial Park and relocated R&D departments (Kobe City, Hyogo Prefecture / now Techno Park).

Kobe Factory (Kobe City, Hyogo Prefecture) Established a new Kobe factory in the Nishijin Industrial Park (Kobe City, Nishiku), relocating R&D department (now Techno Park)

PAMIA-10 Launched the "Immuno Agglutination Analyzer PAMIA-10" which measures trace proteins in serum using a proprietary immune measurement method, entering the immunology field

Reizo Hashimoto became president. Declared "Aim to be the world leader in hematology within 10 years" and "Sales composition ratio of new businesses to exceed 40%."

Reizo Hashimoto appointed as president Declared "Aim to be the world leader in hematology within 10 years" and "Sales ratio of new businesses to exceed 40%"

R-1000 Launched the "Automatic Reticulocyte Analyzer R-1000" which enables automatic measurement of reticulocytes for the first time in the world

Simultaneous measurement of blood cell count and white blood cell classification, thoroughly implementing biohazard countermeasures, launched the "Multi-parameter Automated Blood Cell Analyzer NE-8000"

Moved headquarters to Chuo Ward, Kobe City (Port Island), consolidating headquarters functions and sales/trade departments

HS Series Launched the "Comprehensive Hematology Testing System HS Series" which automates blood cell count, white blood cell classification, reticulocyte count, and smear preparation for the first time in the world

UA-1000 Launched the "Automatic Urinalysis Analyzer UA-1000" entering the urinalysis field with in-house developed products

Established Japan's first diagnostic reagent production factory (Ono City, Hyogo Prefecture). Started direct sales, service, and support overseas (UK). Established the company's first overseas sales subsidiary, TOA MEDICAL ELECTRONICS (UK) LTD. (now Sysmex UK Limited).

Established Ono Factory in Ono City, Hyogo Prefecture, as the first domestic diagnostic drug manufacturing plant, relocating the diagnostic drug production department

Toa Medical Electronics (UK) Ltd. Started overseas direct sales, service, and support (UK) Established the first overseas sales subsidiary, the UK local corporation Toa Medical Electronics (UK) Ltd. (now Sysmex UK Limited)

Established Sysmex TMC Corporation

Started production of diagnostic reagents overseas (Germany). Established the European diagnostic reagent production base, Neumuenster Factory. Established the US diagnostic reagent production base, Sysmex Corporation of America (now Sysmex Reagents America, Inc.).

Neu Münster Factory (Germany) Established Neu Münster Factory as a new European diagnostic drug production base

Sysmex Corporation of America (Currently Sysmex Reagents America, Inc. (USA)) Established the local subsidiary Sysmex Corporation (currently Sysmex Reagents America, Inc.) in the USA

Initiated the development of the Asia-Pacific region. Opened a驻在员 office in Singapore.

Started developing the Asia-Pacific regional base

Opened a resident office in Singapore

Accelerated business expansion in blood coagulation testing. Signed a business alliance with Dade International (now Siemens Healthcare Diagnostics) for the sale of blood coagulation testing products. Developed a supply and technical service system for diagnostic reagents in China. Established a joint venture company, Jinan East Asia Medical Electronics Co., Ltd. (now Jinan Kisen Mikang Medical Electronics Co., Ltd.) in Jinan, China.

Listed on the Osaka Securities Exchange Second Section. Strengthening management structure through activities leading to listing (listed on the Tokyo Stock Exchange Second Section in the following year 1996, promoted to Osaka Securities Exchange and Tokyo Stock Exchange First Section in 2000)

Established the German local corporation Sysmex GmbH Deutschland (now Sysmex Deutschland GmbH)

Signed a business alliance with Deid International (now Siemens Healthineers Diagnostics) for the sale of coagulation products

Sainan Kisen Mikanko Medical Electronics Co., Ltd.

Press conference for establishment

Establishment of diagnostic reagent supply and technical service system in China

Establishment of a joint venture in China, Sainan East Asia Medical Electronics Co., Ltd. (now Sainan Kisen Mikanko Medical Electronics Co., Ltd.)

Acquired ISO9001 certification, an international quality assurance standard

SF-3000

Launch of the

Promotion of the spread of white blood cell classification devices in small and medium-sized laboratories

Launch of clinical testing information system

UF-100

Listed on Osaka Securities Exchange Market Second Section

Launch of the

Tsuneyoshi Ieji (current Chairman and Group CEO) appointed as President. Declared aim to evolve from a specialized manufacturer to a distinctive global comprehensive manufacturer.

Listed on Tokyo Stock Exchange Second Section

Listed on Tokyo Stock Exchange Market Second Section

Tsuneyoshi Ieji

(Current Chairman and Group CEO)

Assumed the position of President

Tsuneyoshi Ieji (current Chairman and Group CEO) assumed the position of President, and

Declared aiming to become a global comprehensive manufacturer with distinctive features from a specialized manufacturer

Established the local subsidiary Sysmex Infosystems America, Inc. (currently Sysmex America, Inc.) in the USA

Establishment of a local subsidiary overseeing the Asia-Pacific region.

Establishment of SYSMEX SINGAPORE PTE LTD. (now Sysmex Asia Pacific Pte Ltd.)

Strengthening global sales network through partnerships with leading healthcare companies worldwide.

Partnership with F. Hoffmann-La Roche (Switzerland) regarding hematology products.

Commencement of diagnostic reagent production in India.

Establishment of joint venture SYSMEX TRANSASIA BIO-MEDICALS PRIVATE LTD. (now Sysmex India Pvt. Ltd.).

Renamed to 'Sysmex Corporation' and relocated headquarters on the 30th anniversary of founding.

Sysmex Singapore Pte Ltd.

(Currently Sysmex Asia Pacific Pte Ltd.)

Established as the regional subsidiary overseeing Asia-Pacific, with the Singapore subsidiary Sysmex Singapore Pte Ltd. (currently Sysmex Asia Pacific Pte Ltd.)

Established the Malaysian subsidiary Sysmex (Malaysia) Sdn Bhd

Partnership with Roche

Basic agreement on global business partnership with F. Hoffmann-La Roche (Switzerland) for sales cooperation and joint research and development

Established a joint venture, Sysmex Transasia Bio-Medicals Private Ltd. (currently Sysmex India Pvt. Ltd.), for manufacturing equipment and diagnostic reagents in India

Obtained certification for international standards for medical device quality assurance "ISO13485" and European standards "EN46001"

Headquarters of Sysmex Corporation

(Kobe City, Hyogo Prefecture)

Renamed to "Sysmex Corporation" and relocated headquarters to Higashi-Shin-Kobe, Kobe City

Sysmex of Brazil

Industria e Comercio Ltda. (Brazil)

Established the Brazilian subsidiary Sysmex do Brasil Industria e Comercio Ltda.

XE-2100

Launched the "Multi-parameter Automated Hematology Analyzer XE-2100"

Realized labor-saving and efficiency in testing operations

First in the world, launched the "Peripheral Blood Vessel Monitoring Device ASTRIM"

Established the Thai subsidiary Sysmex (Thailand) Co., Ltd.

Customer Support Center

Established Hong Kong subsidiary Sysmex MHC Hong Kong Limited

Establishment of a local subsidiary overseeing the China region.

Establishment of Sysmex Shanghai Ltd. (Ximos Medical Electronics (Shanghai) Co., Ltd.).

Expansion of global production system for stable supply of diagnostic reagents.

Start of diagnostic reagent production at local subsidiaries in Brazil and Singapore.

Initiation of challenges in the life sciences field.

Established a central research institute within the Techno Center (now Techno Park) in Kobe, Hyogo Prefecture.

Sysmex Shanghai Ltd. (Kisore Mikkang Medical Electronics (Shanghai) Co., Ltd.) Established the local subsidiary Kisore Mikkang Medical Electronics (Shanghai) Co., Ltd.

Started production of diagnostic reagents in Brazil

Promoted to First Section of the Tokyo Stock Exchange and Osaka Securities Exchange Market

Establishment of the local subsidiary Sysmex France S.A.R.L (now Sysmex France S.A.S.) in France

Central Research Institute (Nishi-ku, Kobe City, Hyogo Prefecture)

Opening of the Central Research Institute at Techno Center (now Techno Park)

Obtained ISO 14001 environmental management system certification at Kakogawa Factory

Establishment of a joint venture Sysmex San Tung Co., Ltd. (now Sysmex Taiwan Co., Ltd.) in Taiwan

Start of diagnostic reagent production in Singapore

Establishment of Africa Service Center, a technical service base in Africa

Launch of the immune agglutination analyzer PAMIA-40i, which shortens testing time by about one-third through whole blood measurement

Participated in capital investment in Delphic Medical Systems, and renamed to Sysmex Delphic Limited (now Sysmex New Zealand Limited)

Strengthening of research and development capabilities for bio-diagnostic reagent production.

Complete acquisition of International Reagents Co., Ltd. (merged in 2022).

Establishment of PT. Sysmex Indonesia, a local subsidiary in Indonesia

Full acquisition of Kokusai Reagent Co., Ltd. (merged in 2022)

Developed a genetic testing technology that can detect the presence of cancer cell metastasis to lymph nodes within 15 minutes

Acquisition of R.A. Systems Co., Ltd. (now Sysmex RA Co., Ltd.)

Start of direct sales and direct service in the United States.

Sysmex America, Inc.

Start of direct sales and direct service in the United States

Merged Sysmex Corporation of America and Sysmex Infosystems America, Inc. to establish Sysmex America, Inc.

Established the local subsidiary Kisore Mikkang Biotechnology (Wuxi) Co., Ltd. (Second Diagnostic Drug Factory)

ASTRIM SU

The peripheral vascular monitoring device ASTRIM SU received the Good Design Award

Acquisition of Sysmex Delphic Limited (now Sysmex New Zealand Limited)

Acquisition of CNA Corporation (now Sysmex CNA Corporation)

The technology for diagnosing immature cell measurement received the

Sysmex BMA Laboratory opened within Port Island, where Kobe City is advancing its Medical Industry City concept.

Sysmex Polska Sp. z o.o. established in Poland.

Solution Center opened in Nishi-ku, Kobe City.

Stock split.

Sysmex Women's Athletics Club established.

Released the high-performance, compact 'Multi-parameter Automated Hematology Analyzer XS Series' that follows the measurement principle of the XE series.

Formulation of the corporate philosophy 'Sysmex Way'.

Sysmex Group corporate philosophy.

Established 'Sysmex Way'.

Established the Sysmex Group corporate philosophy 'Sysmex Way'.

Opened Tokyo branch and metropolitan service center.

Released three items of the 'Respiratory Infection Rapid Diagnostic Kit Pukutem S Series'.

Sysmex Austria GmbH established in Austria.

Sysmex Slovaloa s.r.o. established in Slovakia.

Released 'Multi-parameter Automated Hematology Analyzer XE-5000'.

Sysmex Hungaria Kft. established in Hungary.

Sysmex Canada, Inc. established in Canada.

Sysmex Ceska Republika S.R.O. (now Sysmex CZ s.r.o.) established in Czech Republic.

Released 'Fully Automatic Immunoassay Analyzer HISCL™-2000i', capable of high-sensitivity, rapid measurement with trace samples.

Revamped corporate logo on the 40th anniversary of founding.

With the concept of "Creation and Inheritance of 'Knowledge'", the core research and development base Techno Park was established (Kobe City, Hyogo Prefecture)

Released 'Breast Cancer Lymph Node Metastasis Rapid Diagnostic System RD-100i', the first domestic system to automate breast cancer lymph node metastasis testing.

Sysmex Middle East FZ-LLC established in Dubai (UAE).

Sysmex's mission: 'Designing the evolution of healthcare.'

Corporate logo symbolizing

Corporate logo renewed on the occasion of the 40th anniversary of establishment.

Techno Park (Nishi-ku, Kobe City, Hyogo Prefecture)

Expanded and renamed the Techno Center to about twice its size, establishing Techno Park as a core R&D hub.

Released Japan's first rapid diagnostic kit for avian influenza in chickens, 'Pukutemu Tri Influenza'.

Established the joint venture company Sysmex Transasia Services Pvt. Ltd. in India.

Co-developed technology with the Osaka Prefectural Public Health Research Institute to quickly and simply detect avian influenza viruses.

Released the new XT series model, the multi-parameter automated hematology analyzer XT-4000i.

Opened an in-house childcare center, Sysmex Kids Park, within Techno Park.

Established the Dutch subsidiary Sysmex Nederland B.V.

Established the Belgian subsidiary Sysmex Belgium N.V.

Opened the China Diagnostic Drug Development Center in Wuxi, China.

Established HITADO GmbH, a sales, service, and support company for POCT-related products in Germany.

Established the Spanish subsidiary Sysmex Espana S.L.

Established the Vietnamese subsidiary Sysmex Vietnam Company Limited.

Formulated the 'Sysmex Group Long-Term Environmental Goals'.

The urinary protein analysis diagnostic reagent received the 2010 National Innovation Award 'Invention Award'.

Started a joint venture with Idex, the leading company in the pet animal testing field.

Agreed on a new business partnership with Marburg concerning industrial particle measurement.

Establishment of the Russian subsidiary Sysmex RUS LLC

Participation in the United Nations' Global Compact

Stock split

Acquisition of the Biochemical Research Laboratory of Katakura Kogyo Co., Ltd.

Global launch of the new model 'XN™ Series Automated Hematology Analyzer' in the hematology field

Technology for white blood cell differential counting method and diagnostic reagents received the 2011 National Innovation Award 'Innovation Prize'

Release of the new model 'CS-5100™ Fully Automated Coagulation Analyzer' in the blood coagulation testing field

Our hematology counting standard instrument was selected as a Chinese national standard

Clinical testing system applying the 'Silent Design™' concept received the 2011 Good Design Gold Award

Provided special sponsorship for the first local citizen marathon 'Kobe Marathon 2011'

Launched a contract service for research tests on early breast cancer recurrence risk

Released the compact model 'XP Series Multiparameter Automated Hematology Counter' in the hematology field

Achieved automation of rapid lymph node metastasis testing for gastric cancer

Established a protein production facility in Nishi-ku, Kobe City

Released the new model 'HISCL™-5000 Fully Automated Immunoassay Analyzer'

Entry into the medical robot market

Jointly established Medicaroid Corporation, a marketing company for medical robot development with Kawasaki Heavy Industries, Ltd.

Accelerate the expansion of technology platforms for personalized medicine

Acquired Partec GmbH of Germany, a pioneer of FCM technology (now Sysmex Partec GmbH)

Acquired Inostics GmbH of Germany, which has technology to highly sensitively measure cancer genes in blood (now Sysmex Inostics GmbH)

XN™-2000 and its diagnostic reagents received the 2013 iF Product Design Award in Germany

Establishment of Sysmex Business Support Co., Ltd.

Sysmex Women's Track and Field Club relocated to Kobe

Established the local subsidiary Sysmex Korea Co., Ltd. in South Korea

Development of particle classification counting method in the multiparameter automated hematology analyzer received the 2013 Minister of Education, Culture, Sports, Science and Technology Award

Opening of Sysmex Forest

Established a Sysmex forest in Ono City, Hyogo Prefecture

Established a research and development base in the Americas, the Americas R&D Center

Press conference for the establishment of Medicaroid Co., Ltd.

Established the local subsidiary Sysmex Turkey Diagnostik Sistemleri Ltd. Sti. in Turkey

Jointly established Medicaroid Co., Ltd., a marketing company for the development of medical robots with Kawasaki Heavy Industries, Ltd.

Acquired Partec Corporation (now Sysmex Partec GmbH) as a subsidiary

Acquired Inostics Corporation (now Sysmex Inostics GmbH) as a subsidiary

The

Hematology field's XN™-2000 and diagnostic drugs for XN™ received the "German Design Award"

Successful development of "HISCL™ M2BPGi™ diagnostic reagent" for liver fibrosis testing technology using glycan markers, a world first

Entry into the gene contract testing business

Participated financially in RIKEN Genesis Co., Ltd. to develop the genetic testing business (became a subsidiary in 2016)

Obtained certification for international standards "ISO/IEC 17025" and "ISO/IEC 17043" for calibration agencies and external quality control

Stock split

Establishment of Sysmex Engineering Co., Ltd.

Establishment of local subsidiary Sysmex Colombia SAS in Colombia

Development of "Urinary Sediment Analysis Method" awarded the Minister of Education, Culture, Sports, Science and Technology Award in 2014

i Square (Kakogawa City, Hyogo Prefecture)

Participated in capital investment in Riken Genesis Co., Ltd., a subsidiary of Toppan Printing Co., Ltd., to develop gene testing business in personalized medicine

Established device manufacturing plant i Square in Kakogawa City, Hyogo Prefecture

The "Automatic Hematology Analyzer CC-1001" first in Japan to be put into practical use, certified as "3rd Analysis Equipment and Scientific Equipment Heritage"

HISCL-800

Launch of the compact model of immunoserum test, "Fully Automated Immunoassay Analyzer HISCL™-800"

Launch of the new model in blood coagulation testing, "Fully Automated Coagulation Analyzer CS-2400/CS-2500"

Establishment of the local subsidiary in Australia, Sysmex Australia Pty Ltd.

Established a new domestic base for companion diagnostics development aimed at realizing personalized medicine within IMP at Kobe Port Island.

Launched the next-generation model for urine sediment examination, "Fully Automated Urine Formed Element Analyzer UF-5000"

Launch of the compact model in hematology, "Multi-parameter Automated Hematology Analyzer XN-L™ Series"

Launch of the compact model for blood coagulation testing, "Fully Automated Coagulation Analyzer CS-1600™"

Invested in iPS Portal Inc. to contribute to regenerative medicine.

Established a global communication center for human resource development.

Obtained certification for international standard "ISO 15195" for clinical testing reference laboratories.

Partnered with LabCorp in the field of cancer gene testing using blood samples.

UF-5000

Launch of next-generation models in urine sediment analysis, "Fully Automated Urine Particle Analyzer UF-5000/UF-4000/UF-3000"

Established a new research and development open innovation lab.

Received the 20th "IR Excellent Company Award" from the Japan IR Association.

Established a lab within the National Cancer Center to promote the development of new cancer diagnostic methods.

Established the local subsidiary in Ghana, Sysmex West and Central Africa Ltd.

Launched a new product in urine qualitative testing, "Fully Automated Urinalysis Chemistry Analyzer UC-3500" for overseas markets.

Launched a new product in urine sediment analysis, "Fully Automated Urine Particle Imaging Unit UD-10".

Acquired RIKEN Genesis Co., Ltd., to develop personalized medicine gene testing business.

Received the "Minister of Economy, Trade and Industry Award" at the 14th Industry-Academia-Government Collaboration Merit Award.

The "Automated Blood Coagulation Analyzer CA-100" was recognized as the "5th Analysis Equipment and Scientific Equipment Heritage"

Selected for the first time in the "Dow Jones Sustainability World Index"

Obtained the "Elvoshi" certification mark for excellent companies based on the Act on Promotion of Women’s Participation and Advancement in the Workplace

Expanded the portfolio of life science businesses, acquired Oxford Gene Technology IP Limited, which has proprietary gene analysis technology

Established Sysmex Harmony Inc. for the promotion of employment of persons with disabilities

Development of white blood cell 5 classification and abnormal white blood cell classification methods received the Minister of Education, Culture, Sports, Science and Technology Award for Science and Technology in 2017

Oxford Gene Technology IP Limited

Holds

High-quality FISH probes,

Acquired NGS diagnostic drug development capability

The "Blood Cell Analyzer for Rapid Evaluation of Iron Therapy Effect" received the 2017 National Invention Award for Invention

Acquired Oxford Gene Technology IP Limited as a subsidiary

Started providing a new network solution "Caresphere™"; launched new products for cancer lymph node metastasis testing system using OSNA™ method, "Gene Amplification Detection Device RD-200" and "LinoAmp™ CK19"; launched new products for blood coagulation testing, "Fully Automated Blood Coagulation Analyzer CN™-6000/CN™-3000"

Started assay service for "OncoGuide™ NCC Oncopanel System" for cancer genome profiling testing

Strengthened diagnostic drug functions for business expansion; established a bio-diagnostic drug base, Techno Park East Site (Kobe City, Hyogo Prefecture)

Jointly established Deepure Medical Solutions Inc., which plans, develops, and operates solution services utilizing open platforms and applications related to digital medicine with Optimum Inc.

Launched the surgical support robot system "hinotori™ Surgical Robot System"

Next-generation flagship model in hematology, "Multi-parameter Automated Blood Cell Analyzer XR™ Series"

Established Sysmex Portugal, S.A., a local subsidiary in Portugal

Launched the next-generation flagship model in hematology, the "Multi-parameter Automated Blood Cell Analyzer XR™ Series," and the compact white blood cell 3 classification model, the "Multi-parameter Automated Blood Cell Counter XQ™ Series"

Signed a contract with ThinkSite Inc. for joint development and capital alliance aimed at commercializing AI-based cell analysis technology

The invention of a dual configuration blood cell analyzer to improve testing speed received the 2021 National Invention Award for Invention

Transitioned to the new market segment "Prime Market"

Accelerated clinical implementation of rapid drug sensitivity testing; acquired Sysmex Astrego AB (formerly Astrego Diagnostics AB)

Launched new product for urine sediment examination, "Fully Automated Urine Formed Element Analyzer UF-1500"

Established a joint venture company, AlliedCel Inc., with JCR Pharmaceuticals Co., Ltd., in the regenerative and cell medicine field

Established Sysmex LLC in Saudi Arabia

Agreed on capital and business alliance with Kainos Co., Ltd. for the development and production of diagnostic drugs in the field of immunodiagnostics

Supported as a silver partner in the "Life to Expand" theme project of the Osaka-Kansai Expo

Acquired Astrego Diagnostics AB (now Sysmex Astrego AB) to accelerate clinical implementation of rapid drug susceptibility testing

To address climate change, which has a serious impact on the global environment, a 'Carbon Neutral Goal' has been set to achieve net-zero greenhouse gas emissions by 2040.

Received the 'Invention Award' at the 2022 National Invention Awards for the invention of a rapid and accurate platelet measurement method using platelet staining.

Launch of hematology specimen transportation system product line.

Launch of the 'Multi-parameter Automated Blood Cell Analyzer XR™ Series' specimen transportation system product line in the hematology field.

Acquisition of Pilot Corporation (now Sysmex Pilot Corporation) as a subsidiary.

Launch of the new product 'Fully Automated Urinary Sediment Analyzer UF-1500' in the urine sediment examination field.

Establishment of a joint venture, AlliedCel Corporation, with JCR Pharmaceuticals Co., Ltd., in the regenerative and cell therapy field.

Launched diagnostic drugs "HISCL™ β-Amyloid 1-42 Diagnostic Reagent" and "HISCL™ β-Amyloid 1-40 Diagnostic Reagent" to examine the accumulation state of brain amyloid β, which causes Alzheimer's disease from a small amount of blood.

Accelerate collaboration with various external partners. Opened Healthcare Science Hub Tokyo (Koto City, Tokyo). Accelerate efforts in regenerative cell therapy. Acquired Megacalion Inc. as a subsidiary to accelerate the early commercialization of platelet preparations derived from human iPS cells.

Signed a global OEM agreement with Siemens Healthineers on products related to blood coagulation testing.

Launched a clinical flow cytometry system in Japan.

Received manufacturing and sales approval for the first domestic genetic panel testing system for hereditary retinal dystrophy, 'PrismGuide™ IRD Panel System'.

Launched diagnostic drugs 'HISCL™ β-Amyloid 1-42' and 'HISCL™ β-Amyloid 1-40' that examine the accumulation of brain amyloid β, a cause of Alzheimer's disease, from small amounts of blood.

Launched the world's first rapid drug susceptibility testing system, 'Rapid Drug Susceptibility Testing System PA-100 AST System', in Europe.

Established Healthcare Science Hub Tokyo, a research and development base.

Entered into a basic business alliance agreement with Sysmex, Fuji Rebio Holdings, Inc., in the field of immunoassay testing.

Opened a new research and development base, Healthcare Science Hub Tokyo, in Shin-Kiba, Tokyo.

Obtained certification for the international guideline 'ISO 30414' on human capital disclosure, the first in Asia's manufacturing industry.

Established a production base for diagnostic drugs and equipment in Gujarat, India.

Stock split.

Started sales of Sysmex brand blood coagulation products in the US and EU countries.

Received the 'Science and Technology Award' at the 2024 Minister of Education, Culture, Sports, Science and Technology Awards for the development of a urine specimen analysis method useful for early disease detection.

The 'Rapid Drug Susceptibility Testing System PA-100 AST System' received the UK's largest science award, the 'Longitude Prize on AMR'.

Establishment of diagnostic drug and equipment production base in India, establishment of diagnostic drug and equipment production base in Gujarat, India

Signed a global alliance agreement with Qiagen Corporation in the field of genetic testing

Industry first, realization of horizontal cycle container for diagnostic drugs and start of sales in Japan

Relocation and expansion of Sysmex RA Co., Ltd. factory in Shiojiri City, Nagano Prefecture

Establishment of local subsidiary Sysmex East Africa Ltd. in Kenya

Establishment of local subsidiary Sysmex Greece I.K.E. in Greece